Xin-Wen Wang

Xin-Wen Wang

Auto-generated profile, based on publicly available information

Xin-Wen Wang

Department of Orthopedic Surgery the First Affiliated Hospital Sun Yat‐Sen University Guangzhou 510080 China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Cell Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
XWXin-Wen Wang
Xin-Wen Wang
YSYong-Jin Sun
Yong-Jin Sun
XCXiao Chen
Xiao Chen
WZWenzhi Zhang
Wenzhi Zhang

20 November 2024 in Advanced Science
Verified
Journal Article
Open access
XWXinwen Wang
Xinwen Wang
MWMin Wang
Min Wang
QLQijun Lin
Qijun Lin
LHLixin He
Lixin He
BZBaolin Zhang
Baolin Zhang
YDYuhu Dai
Yuhu Dai
Acquired resistance to hormonal therapy, particularly enzalutamide (ENZ), remains a significant obstacle in the treatment of advanced bone metastatic prostate cancer. Here, it is demonstrated that under ENZ treatment, osteoblasts in the bone microenvironment secrete increased levels of extracellular matrix protein 1 (ECM1), which affects surrounding prostate cancer cells, promoting tumor cell proliferation and anti‐androgen resistance. Mechanistically, ECM1 interacts with the enolase 1 (ENO1) receptor on the prostate cancer cell membrane, leading to its phosphorylation at the Y189 site. This event further recruits adapter proteins including growth factor receptor‐bound protein 2 (GRB2) and son of sevenless homolog 1 (SOS1), which activates the downstream mitogen‐activated protein kinase (MAPK) signaling pathway to induce anti‐androgen resistance. Furthermore, inhibiting ECM1 or utilizing the ENO1‐targeting inhibitor phosphonoacetohydroxamate (PhAH) significantly restores tumor cell sensitivity to ENZ. Taken together, a potential mechanism is identified through which osteoblast‐derived ECM1 drives resistance in bone metastatic prostate cancer under ENZ treatment. Additionally, the findings indicate that ECM1 and ENO1 may serve as potential targets for developing therapies for bone metastatic castration‐resistant prostate cancer.